MeiraGTx (MGTX) to Release Quarterly Earnings on Thursday

MeiraGTx (NASDAQ:MGTX) is anticipated to issue its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect MeiraGTx to post earnings of ($0.60) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 13, 2026 at 12:30 PM ET.

MeiraGTx Stock Down 0.3%

MGTX opened at $7.41 on Thursday. The stock has a market capitalization of $596.43 million, a price-to-earnings ratio of -3.51 and a beta of 1.37. MeiraGTx has a 12 month low of $4.55 and a 12 month high of $9.73. The company has a debt-to-equity ratio of 26.29, a current ratio of 0.22 and a quick ratio of 0.22. The business has a 50-day moving average of $7.65 and a two-hundred day moving average of $7.95.

Wall Street Analyst Weigh In

MGTX has been the subject of a number of research reports. HC Wainwright assumed coverage on MeiraGTx in a research report on Monday, November 24th. They set a “buy” rating and a $20.00 price target for the company. Zacks Research lowered MeiraGTx from a “hold” rating to a “strong sell” rating in a research note on Friday, January 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of MeiraGTx in a report on Thursday, January 22nd. Piper Sandler increased their target price on shares of MeiraGTx from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $35.00 price target on shares of MeiraGTx in a research report on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, MeiraGTx presently has an average rating of “Moderate Buy” and an average price target of $26.00.

Institutional Investors Weigh In On MeiraGTx

Hedge funds have recently bought and sold shares of the business. Perceptive Advisors LLC increased its stake in MeiraGTx by 0.4% during the second quarter. Perceptive Advisors LLC now owns 12,626,103 shares of the company’s stock valued at $82,231,000 after purchasing an additional 45,000 shares during the last quarter. Rubric Capital Management LP boosted its holdings in shares of MeiraGTx by 65.7% in the 4th quarter. Rubric Capital Management LP now owns 6,175,331 shares of the company’s stock valued at $49,094,000 after buying an additional 2,448,880 shares during the period. Adage Capital Partners GP L.L.C. grew its position in shares of MeiraGTx by 7.1% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 6,034,578 shares of the company’s stock valued at $39,345,000 after buying an additional 400,000 shares during the last quarter. Millennium Management LLC raised its stake in MeiraGTx by 23.5% during the fourth quarter. Millennium Management LLC now owns 3,176,390 shares of the company’s stock worth $25,252,000 after acquiring an additional 604,121 shares during the period. Finally, State Street Corp lifted its holdings in MeiraGTx by 7.1% in the fourth quarter. State Street Corp now owns 729,445 shares of the company’s stock worth $5,799,000 after acquiring an additional 48,414 shares during the last quarter. Institutional investors and hedge funds own 67.48% of the company’s stock.

About MeiraGTx

MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx’s pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.

The company’s lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders.